Discounted Cash Flow
Can-fite Biopharma Ltd. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $165.0k | $8.3m | $-34.4m | 5004.2% | $0.96 |
| 2017 | $789.0k (378.2%) | $6.3m (-23.2%) | $-9.6m (72.2%) | 803.4% (-83.9%) | $0.15 (-84.4%) |
| 2018 | $3.8m (384.2%) | $6.6m (3.7%) | $-4.2m (56.2%) | 172.0% (-78.6%) | $0.17 (13.3%) |
| 2019 | $2.0m (-46.8%) | $-9.6m (-245.9%) | $-10.8m (-158.0%) | -471.8% (-374.3%) | $-0.11 (-164.7%) |
| 2020 | $763.0k (-62.5%) | $-14.4m (-50.7%) | $-12.1m (-11.9%) | -1892.9% (-301.2%) | $-0.04 (63.6%) |
| 2021 | $853.0k (11.8%) | $-12.6m (12.7%) | $-9.9m (18.4%) | -1478.9% (21.9%) | $-0.03 (25.0%) |
| 2022 | $810.0k (-5.0%) | $-10.2m (19.4%) | $-10.8m (-9.5%) | -1255.9% (15.1%) | $-0.01 (66.7%) |
| 2023 | $743.0k (-8.3%) | $-7.6m (25.0%) | $-8.4m (21.9%) | -1027.5% (18.2%) | $-0.01 (0.0%) |
| 2024 | $674.0k (-9.3%) | $-7.9m (-3.2%) | $-7.6m (9.5%) | -1169.1% (-13.8%) | $0.00 (100.0%) |
| 2025 | $405.0k (-39.9%) | $-9.8m (-24.7%) | $-9.0m (-17.1%) | -2426.7% (-107.6%) | $-5.97 |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.